Evidence mapPaperPMID 39353069Full record

ArticleEuropean journal of endocrinology2024

Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans.

Felix A Westcott, Shilpa R Nagarajan, Sion A Parry, Dragana Savic, Charlotte J Green, Thomas Marjot, Elspeth Johnson, Thomas Cornfield, Ferenc E Mózes, Paige O'Rourke and 6 more

Abstract read
In one paragraph

Article in European journal of endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Felix A WestcottOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.ORCID 0000-0002-5315-7963
Shilpa R NagarajanOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Sion A ParryOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Dragana SavicOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Charlotte J GreenOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Thomas MarjotOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Elspeth JohnsonOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.ORCID 0000-0003-4173-7837
Thomas CornfieldOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Ferenc E MózesOxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, OX3 9DU, United Kingdom.
Paige O'RourkeOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Jessica MendallOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
David DearloveOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Barbara FieldingOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Kieran SmithOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Jeremy W TomlinsonOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.
Leanne HodsonOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LE, United Kingdom.ORCID 0000-0002-2648-6526

Funding

Biotechnology and Biological Sciences Research Council BB/N005600/1Biotechnology and Biological Sciences Research Council Institute Strategic Programme Food Innovation and Health BB/R012512/1British Heart Foundation FS/11/18/28633Kennedy Trust Oxford MB PhD ProgrammeMedical Research Council MR/P011462/1NIHR Oxford Biomedical Research CentreNovo Nordisk Postdoctoral FellowshipOxford BHF CRE RE/18/3/34214University of Oxford
6 · The paper itself

Abstract

objectiveFasting hyperglycemia and hypertriglyceridemia are characteristic of insulin resistance (IR) and rodent work has suggested this may be due to selective hepatic IR, defined by increased hepatic gluconeogenesis and de novo lipogenesis (DNL), but this has not been shown in humans.

designCross-sectional study in men and women across a range of adiposity.

methodsMedication-free participants (n = 177) were classified as normoinsulinemic (NI) or hyperinsulinemic (HI) and as having low (LF) or high (HF) liver fat content measured by magnetic resonance spectroscopy. Fractional gluconeogenesis (frGNG) and hepatic DNL were measured using stable isotope tracer methodology following an overnight fast.

resultsAlthough HI and HF groups had higher fasting plasma glucose and triglyceride concentrations when compared to NI and LF groups respectively, there was no difference in frGNG. However, HF participants tended to have lower frGNG than LF participants. HI participants had higher DNL compared to NI participants but there was no difference observed between liver fat groups.

conclusionsTaken together, we found no metabolic signature of selective hepatic IR in fasting humans. DNL may contribute to hypertriglyceridemia in individuals with HI but not those with HF. Glycogenolysis and systemic glucose clearance may have a larger contribution to fasting hyperglycemia than gluconeogenesis, especially in those with HF, and these pathways should be considered for therapeutic targeting.

Indexed as

FastingInsulin ResistanceLiverAdultBiomarkersBlood GlucoseCross-Sectional StudiesFemaleGluconeogenesisHumansHyperinsulinismLipogenesisMaleMiddle AgedTriglyceridesBiomarkersBlood GlucoseTriglyceridesde novo lipogenesisgluconeogenesishyperinsulinemiainsulin resistanceliver fat

Identifiers

PMID39353069
PMCPMC11497584

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.